MINO

The MINO cell line is a human-derived model of mantle cell lymphoma (MCL), a rare and aggressive subtype of B-cell non-Hodgkin lymphoma. This cell line was established from a 64-year-old female patient with advanced MCL. It is characterized by overexpression of cyclin D1 due to the chromosomal translocation t(11;14)(q13;q32), a hallmark of MCL. MINO cells exhibit a CD5+CD20+CD23? immunophenotype, consistent with MCL diagnosis, and show additional genetic alterations, including hyperdiploidy and a TP53 mutation at codon 147 (valine to glycine), which may contribute to its pathogenesis. MINO cells grow as single cells or in small clumps and demonstrate features typical of MCL, such as high levels of phosphorylated retinoblastoma protein (pRB) and expression of anti-apoptotic proteins like Bcl-2 and Bcl-xL. These cells have been used to study the molecular mechanisms underlying MCL progression and resistance to therapy. In particular, studies have shown that cyclin D1 plays a role in promoting cell cycle progression and evasion of apoptosis by interacting with pro-apoptotic proteins like Bax, favoring lymphoma cell survival. The MINO cell line is a valuable tool for preclinical research, including drug testing and genetic studies. It has been employed in evaluating targeted therapies that inhibit cyclin D1 activity or disrupt pathways critical to MCL survival, such as the PI3K/Akt and Bcl-2 pathways. This cell line continues to contribute to understanding MCL biology and improving therapeutic strategies for this challenging disease. Lymphoma cell lines, Peripheral blood, Mantle cell lymphoma, Growth Conditions: Suspension, Biosafety level: BSL 1